253 related articles for article (PubMed ID: 27578487)
1. Biosimilar structural comparability assessment by NMR: from small proteins to monoclonal antibodies.
Japelj B; Ilc G; Marušič J; Senčar J; Kuzman D; Plavec J
Sci Rep; 2016 Aug; 6():32201. PubMed ID: 27578487
[TBL] [Abstract][Full Text] [Related]
2. SpeB proteolysis with imaged capillary isoelectric focusing for the characterization of domain-specific charge heterogeneities of reference and biosimilar Rituximab.
Zhang Z; Perrault R; Zhao Y; Ding J
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 May; 1020():148-57. PubMed ID: 27038651
[TBL] [Abstract][Full Text] [Related]
3. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.
Lee KH; Lee J; Bae JS; Kim YJ; Kang HA; Kim SH; Lee SJ; Lim KJ; Lee JW; Jung SK; Chang SJ
MAbs; 2018 Apr; 10(3):380-396. PubMed ID: 29469653
[TBL] [Abstract][Full Text] [Related]
4. A demonstration of analytical similarity comparing a proposed biosimilar pegfilgrastim and reference pegfilgrastim.
Brokx S; Scrocchi L; Shah N; Dowd J
Biologicals; 2017 Jul; 48():28-38. PubMed ID: 28619479
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Structural, Biological, and Functional Similarity of Biosimilar Granulocyte Colony Stimulating Factor to its Reference Product.
Bor Tekdemir Z; Seckin AI; Kacar T; Yilmaz E; Bekiroglu S
Pharm Res; 2020 Oct; 37(11):215. PubMed ID: 33026512
[TBL] [Abstract][Full Text] [Related]
6. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
Ishii-Watabe A; Kuwabara T
Drug Metab Pharmacokinet; 2019 Feb; 34(1):64-70. PubMed ID: 30600193
[TBL] [Abstract][Full Text] [Related]
7. Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars.
Ghasriani H; Hodgson DJ; Brinson RG; McEwen I; Buhse LF; Kozlowski S; Marino JP; Aubin Y; Keire DA
Nat Biotechnol; 2016 Feb; 34(2):139-41. PubMed ID: 26849514
[No Abstract] [Full Text] [Related]
8. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®.
Xu Y; Xie L; Zhang E; Gao W; Wang L; Cao Y; Xie MH; Jiang W; Liu S
MAbs; 2019 Apr; 11(3):606-620. PubMed ID: 30794092
[TBL] [Abstract][Full Text] [Related]
9. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.
Nupur N; Chhabra N; Dash R; Rathore AS
MAbs; 2018 Jan; 10(1):143-158. PubMed ID: 29200314
[TBL] [Abstract][Full Text] [Related]
10. Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product.
Halim LA; Márquez M; Maas-Bakker RF; Castañeda-Hernández G; Jiskoot W; Schellekens H
Pharm Res; 2018 Oct; 35(11):226. PubMed ID: 30280277
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the higher order structure of Humira®, Remicade®, Avastin®, Rituxan®, Herceptin®, and Enbrel® by 2D-NMR fingerprinting.
Hodgson DJ; Ghasriani H; Aubin Y
J Pharm Biomed Anal; 2019 Jan; 163():144-152. PubMed ID: 30296716
[TBL] [Abstract][Full Text] [Related]
12. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
[TBL] [Abstract][Full Text] [Related]
13. Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products.
Kwon O; Joung J; Park Y; Kim CW; Hong SH
Biologicals; 2017 Jul; 48():101-108. PubMed ID: 28495312
[TBL] [Abstract][Full Text] [Related]
14. Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering.
Trabik YA; Moenes EM; Al-Ghobashy MA; Nebsen M; Ayad MF
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1159():122359. PubMed ID: 32920338
[TBL] [Abstract][Full Text] [Related]
15. Differentiating biosimilarity and comparability in biotherapeutics.
Azevedo V; Hassett B; Fonseca JE; Atsumi T; Coindreau J; Jacobs I; Mahgoub E; O'Brien J; Singh E; Vicik S; Fitzpatrick B
Clin Rheumatol; 2016 Dec; 35(12):2877-2886. PubMed ID: 27734233
[TBL] [Abstract][Full Text] [Related]
16. Development of biosimilars.
Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
[TBL] [Abstract][Full Text] [Related]
17. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars.
Kang J; Halseth T; Vallejo D; Najafabadi ZI; Sen KI; Ford M; Ruotolo BT; Schwendeman A
Anal Bioanal Chem; 2020 Jan; 412(3):763-775. PubMed ID: 31853605
[TBL] [Abstract][Full Text] [Related]
18. Structural similarity, characterization of Poly Ethylene Glycol linkage and identification of product related variants in biosimilar pegfilgrastim.
Shekhawat R; Shah CK; Patel A; Srinivasan S; Kapoor P; Patel S; Kumar S; Sonar S; More N; Joshi M; Patel J; Vachhani M; Kodaganti BP; Choavatiya U; Pushpaja A; Argade S; Nuwal N; Kumar M; Khambhampaty S
PLoS One; 2019; 14(3):e0212622. PubMed ID: 30865643
[TBL] [Abstract][Full Text] [Related]
19. NMR based quality evaluation of mAb therapeutics: A proof of concept higher order structure biosimilarity assessment of trastuzumab biosimilars.
Joshi S; Khatri LR; Kumar A; Rathore AS
J Pharm Biomed Anal; 2022 May; 214():114710. PubMed ID: 35290923
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
